Lundbeck expands its pipeline - initiating phase II clinical trials with a new compound for the treatment of schizophrenia

H. Lundbeck A/S (Lundbeck) expands its pipeline of pharmaceuticals in
clinical development by initiating phase II trials with the compound
Lu AE58054. The compound is a new pharmaceutical candidate in
Lundbeck's portfolio and represents a novel approach to the treatment
of schizophrenia.

Lu AE58054 has shown positive results in a number of preclinical
trials, which documented the compound's ability to improve cognition.
Affecting other areas of the brain than traditional anti-psychotics,
the compound has an effect that breaks with tradition. In this way,
Lu AE58054 complements the existing anti-psychotics by improving the
general clinical efficacy of the overall treatment. Consequently,
Lundbeck expects that Lu AE58054 will improve the daily functioning
of the patients and for example improve their ability to solve
practical problems in their daily lives.

Based on the positive preclinical data and positive outcomes of phase
I trials in healthy individuals, Lundbeck has now launched a phase II
trial with two treatment groups of 60 patients each. The first group
will receive treatment with risperidone and placebo, while the other
will receive risperidone and Lu AE58054. The treatment period will
run for three months. The trial has just been initiated, and
preliminary results are expected by the end of 2009."I'm very pleased that we're able to commence trials with a novel
treatment of schizophrenia, which is a severe disorder," says
Executive Vice President Anders Gersel Pedersen, Head of Drug
Development at Lundbeck.

The global market for anti-schizophrenic pharmaceuticals was valued
at approximately DKK 100 billion in 2007, making it the largest
single market for pharmaceuticals for the treatment of neurological
disorders.

Lundbeck acquired the global rights to Lu AE58054 in connection with
the acquisition of US biotech company Saegis Pharmaceuticals, Inc. in
early 2007. Lu AE58054 is a potent and selective so-called 5-HT6
receptor antagonist.

The 5-HT6 receptor is primarily found in areas of the brain involved
in cognition. A number of early trials have demonstrated that 5-HT6
could offer potential in the treatment of disorders such as
schizophrenia, but also other diseases that may lead to cognitive
disturbances.

About schizophrenia
Schizophrenia is a serious and often chronic mental disorder
affecting approximately 1% of the population, leading to severe
changes in the patient's way of thinking and perceiving the outside
world. In many patients, the disorder starts during late adolescence
or early adulthood. Suicide is a major cause of premature deaths
among patients with schizophrenia. Schizophrenia is also associated
with increased medical morbidity like respiratory or cardiovascular
diseases.

During the course of the illness, periods during which the patient is
in an acute psychotic condition, suffering from definite
hallucinations and delusions alternate with more stable periods
during which the patient experiences a significant reduction in
symptoms. However, even in stable periods, many patients suffer from
cognitive disturbances that make it difficult to establish and
maintain social contacts, complete an education programme, hold a
normal job and generally to lead an independent life.

Schizophrenia is often disabling and produces serious emotional and
financial hardship for the patient and the patient's family.
Furthermore, the disorder causes a major economic burden to society,
not only due to the direct treatment costs but also because of a
reduced ability to work forcing many patients to claim social
security benefits.

The content of this release will have no influence on the Lundbeck
Group's financial result for 2008.

Lundbeck contacts


Investors:                 Media:

Jacob Tolstrup             Jens Harder Højbjerg
Director                   Media Relations Manager
+45 36 43 30 79            +45 36 43 28 33

Palle Holm Olesen
Head of Investor Relations
+45 36 43 24 26


Stock Exchange Release No 357 - 25 November 2008

About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of
pharmaceuticals for the treatment of psychiatric and neurological
disorders. In 2007, the company's revenue was DKK 11 billion
(approximately EUR 1.5 billion or USD 2.0 billion). The number of
employees is approx. 5,300 globally. For more information, please
visit www.lundbeck.com.